Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

Inclusion Criteria: * Parent (or legal guardian) is willing and able to provide written informed consent for child study participation. Additionally, for children whose assent is required per site institutional review board/ethics committee (IRB/EC) policies and procedures, child is willing and able to provide written assent for his or her study participation. * Age less than 18 years at enrollment * HIV-uninfected, or HIV-infected (see the protocol for more information on this criterion) * If HIV-infected: Initiated the standard of care antiretroviral therapy (ART) regimen at least two weeks prior to enrollment (note: regimens including efavirenz \[EFV\], nevirapine \[NVP\], a boosted protease inhibitor \[PI\], or integrase strand transfer inhibitor \[INSTI\] are allowed) * Confirmed or probable MDR-TB classified as follows: * Confirmed MDR-TB (or rifampicin mono-resistant TB \[RMR-TB\], pre-extensively drug-resistant \[XDR\] or XDR-TB): * Intra-thoracic (pulmonary) TB based on chest radiograph consistent with TB, and/or any of the following forms of extrathoracic TB: * 1\) Peripheral TB lymphadenitis * 2\) Pleural effusion or fibrotic pleural lesions * 3\) Stage 1 TB meningitis * 4\) Miliary and abdominal TB * 5\) Other non-disseminated forms of TB disease (see also exclusion criterion below) * AND * Microbiological confirmation of Mycobacterium tuberculosis from any clinical specimen by either culture or molecular methods (including Xpe…